GlassScriptPhysician profile
Christopher G Okiishi
NPI 1598750432
$13,126.85
in general payments reported to CMS, 2019-2025
25 companies · $52.92 in 2025
The $52.92 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,151 · 2021: $1,017 · 2022: $156 · 2023: $38.86 · 2024: $45.29 · 2025: $52.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,377.00 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $430.12 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $354.79 | 2019-2021 | |
| Abbvie INC. | $196.83 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $181.93 | 2019-2024 | Austedo Xr |
| Bausch Health US, LLC | $162.87 | 2019-2021 | |
| Adlon Therapeutics L.P. | $161.47 | 2020-2021 | |
| Tris Pharma INC | $155.79 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $155.71 | 2019-2022 | |
| Lundbeck LLC | $131.70 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $129.55 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.52 | 2021 | |
| Neos Therapeutics, LP | $105.28 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $85.97 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $76.66 | 2020-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $60.23 | 2019 | |
| Eisai INC. | $53.14 | 2020 | |
| Vertical Pharmaceuticals, LLC | $48.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.60 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.72 | 2021 | |
| Almatica Pharma LLC | $21.25 | 2021 | |
| Axsome Therapeutics, INC. | $18.54 | 2023 | Auvelity |
| Corium, LLC | $18.30 | 2022-2024 | Azstarys |
| Alkermes, INC. | $18.21 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Okiishi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.